GlassScriptPhysician profile
Donald Scott Featherman
NPI 1982713632
$3,433.80
in general payments reported to CMS, 2019-2025
20 companies · $525 in 2025
The $525 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $200 · 2021: $419 · 2022: $511 · 2023: $561 · 2024: $746 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $685.69 | 2019-2025 | Dyanavel Xr, Quillichew Er |
| Corium, LLC | $405.25 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $358.68 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Pfizer INC. | $350.06 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $232.87 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $225.90 | 2019-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $204.32 | 2019-2022 | |
| Sobi, INC | $153.74 | 2019-2023 | |
| Kaleo, INC. | $137.88 | 2019-2023 | Auvi-Q |
| Glaxosmithkline, LLC. | $125.88 | 2019-2024 | Bexsero |
| Collegium Pharmaceutical, INC. | $93.34 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $86.50 | 2019-2023 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $80.43 | 2023-2024 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $58.58 | 2024 | |
| Adlon Therapeutics L.P. | $52.24 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $47.68 | 2024 | Ycanth |
| Sanofi Pasteur INC. | $39.27 | 2021-2024 | |
| Seqirus USA INC | $35.30 | 2024 | Flucelvax |
| Photonicare INC | $30.65 | 2025 | Otosight Middle Ear Scope |
| Supernus Pharmaceuticals, INC. | $29.54 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Featherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.